Emergent Biosolutions (NYSE:EBS) is scheduled to be releasing its earnings data after the market closes on Thursday, February 21st. Analysts expect Emergent Biosolutions to post earnings of $0.61 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

EBS stock opened at $65.66 on Thursday. Emergent Biosolutions has a one year low of $46.49 and a one year high of $73.89. The company has a current ratio of 5.52, a quick ratio of 4.29 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.32 billion, a PE ratio of 34.56, a P/E/G ratio of 1.02 and a beta of 1.38.

In related news, Chairman Fuad El-Hibri sold 45,832 shares of the business’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $69.79, for a total value of $3,198,615.28. Following the sale, the chairman now owns 1,428,502 shares in the company, valued at $99,695,154.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sue Bailey sold 17,717 shares of the business’s stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $69.62, for a total transaction of $1,233,457.54. Following the completion of the sale, the director now owns 57,216 shares in the company, valued at approximately $3,983,377.92. The disclosure for this sale can be found here. Insiders sold 98,722 shares of company stock worth $6,885,390 in the last 90 days. 13.40% of the stock is currently owned by company insiders.

Several research firms have recently commented on EBS. Cowen reissued a “hold” rating and issued a $64.00 target price on shares of Emergent Biosolutions in a report on Tuesday, November 20th. Argus set a $80.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Friday, November 9th. Zacks Investment Research reissued a “hold” rating on shares of Emergent Biosolutions in a report on Tuesday, November 13th. Cantor Fitzgerald boosted their target price on shares of Emergent Biosolutions from $68.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, November 2nd. Finally, Wells Fargo & Co set a $65.00 target price on shares of Emergent Biosolutions and gave the stock a “hold” rating in a report on Wednesday, December 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $68.13.

WARNING: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/emergent-biosolutions-ebs-to-release-quarterly-earnings-on-thursday/2819046.html.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Recommended Story: Catch-Up Contributions

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.